This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Researchers examined pregnancy outcomes in 102 patients with essential thrombocythemia.
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.
Pediatric essential thrombocythemia is usually low risk; watching and waiting is a feasible management approach for asymptomatic patients.
Prolonged-release administration of anagrelide resulted in a noninferior decrease in mean platelet levels compared with immediate-release administration.
Treatments for essential thrombocythemia (ET) comprising hydroxyurea and alkylating agents did not appear to impact development of secondary malignancies in patients with ET.
Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
